The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours.
The first was Eidos Therapeutics (NASDAQ: EIDX), which raised $106 million in its stock market debut. The San Francisco company priced its IPO late Tuesday, selling 6.25 million shares at $17 each, which was on the high end of its projected $15 to $17 range. Eidos will use the cash to fund studies of AG10, a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the… Read more »
UNDERWRITERS AND PARTNERS